CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56

Hereditary spastic paraplegia (HSP) is an inherited disorder of the central nervous system mainly characterized by gradual spasticity and weakness of the lower limbs. SPG56 is a rare autosomal recessive early onset complicated form of HSP caused by mutations in CYP2U1. The CYP2U1 enzyme was shown to catalyze the hydroxylation of arachidonic acid. Here, we report two further SPG56 families carrying three novel CYP2U1 missense variants and the development of an in vitro biochemical assay to determine the pathogenicity of missense variants of uncertain clinical significance. We compared spectroscopic, enzymatic, and structural (from a 3D model) characteristics of the over expressed wild‐type or mutated CYP2U1 in HEK293T cells. Our findings demonstrated that most of the tested missense variants in CYP2U1 were functionally inactive because of a loss of proper heme binding or destabilization of the protein structure. We also showed that functional data do not necessarily correlate with in silico predictions of variants pathogenicity, using different bioinformatic phenotype prediction tools. Our results therefore highlight the importance to use biological tools, such as the enzymatic test set up in this study, to evaluate the effects of newly identified variants in clinical settings. SPG56 is a rare early onset complicated form of HSP caused by mutations in CYP2U1, an enzyme that catalyze the hydroxylation of Arachidonic Acid. We report SPG56 families carrying novel CYP2U1 variants and the development of an in vitro biochemical assay allowing the determination of the pathogenicity of missense variants. Comparison of spectroscopic, enzymatic and structural characteristics of the wild‐type or mutated CYP2U1 led us demonstrate the disease‐causing status of some variants due to the loss of proper heme binding to the protein or a modification in CYP2U1 structure.